TY - JOUR
T1 - Radiation-Induced Fibrosis
T2 - Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016.
AU - Citrin, Deborah E.
AU - Prasanna, Pataje G.S.
AU - Walker, Amanda J.
AU - Freeman, Michael L.
AU - Eke, Iris
AU - Barcellos-Hoff, Mary Helen
AU - Arankalayil, Molykutty J.
AU - Cohen, Eric P.
AU - Wilkins, Ruth C.
AU - Ahmed, Mansoor M.
AU - Anscher, Mitchell S.
AU - Movsas, Benjamin
AU - Buchsbaum, Jeffrey C.
AU - Mendonca, Marc S.
AU - Wynn, Thomas A.
AU - Coleman, C. Norman
N1 - Publisher Copyright:
© 2017 by Radiation Research Society.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.
AB - A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF, (c) discuss opportunities for pharmacological mitigation, intervention and modulation of specific molecular pathways, (d) consider the design of optimal clinical trials for mitigation and treatment and (e) outline key regulatory nonprescriptive frameworks for approval.
UR - http://www.scopus.com/inward/record.url?scp=85021883280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021883280&partnerID=8YFLogxK
U2 - 10.1667/RR14784.1
DO - 10.1667/RR14784.1
M3 - Review article
C2 - 28489488
AN - SCOPUS:85021883280
SN - 0033-7587
VL - 188
SP - 1
EP - 20
JO - Radiation research
JF - Radiation research
IS - 1
ER -